NHS England Low Priority Treatment - omega-3 fatty acid compounds by all CCGs

Why it matters: Omega-3 fatty acid compounds are licensed to treat elevated triglycerides, but evidence of benefit is weak. NICE recommend that they are not prescribed for primary prevention of cardiovascular disease.

Description: Cost of omega-3 fatty acid compounds per 1000 patients

Performance: Loading...


Tagged as: Cardiovascular system, Cost Saving, Efficacy, NHS England Low Priority, NICE (or browse all measures)

CCGs are ordered by mean percentile over the past six months. Each chart shows the results for the individual CCG, plus deciles across all CCGs in the NHS in England.

View measure for NHS England combined →

Fetching data...

Do you need help with your analysis? Don't forget to check the FAQ page, and if you have questions.